Vybion news

Vybion announces the issue by the USPTO of Patent No. 9932394 entitled, "Single Chain Intrabodies that Alter Huntingtin Mutant Degradation". Issued claims cover composition of matter as well as both the Huntingtin and Tau protein targets with the potential for treatment of both Huntington`s and Alzheimer`s diseases. A continuation on the remaining methods claims has been filed. This patent application is also pending in multiple jurisdictions in Europe and Asia.

Vybion, Inc. is pleased to announce that its patent application covering methods of use and composition for INT41 Gene Therapy received Track I status from the USPTO. The INT41 patent application covers several neurodegenerative diseases in addition to Huntington`s Disease including Spinal Cerebellar Ataxia, Spinal Muscular Atrophy, and Alzheimer`s. "Vybion is pleased to receive Track I status on INT41 and anticipates rapid review and allowance

Vybion (NY) conducted a webinar, sponsored by the Huntington`s Disease Society of America (HSDA), for patients and caregivers on a new Gene Therapy drug called INT41. The company CEO described this new drug class called Intrabodies and how INT41 works in Huntington`s Disease along with clinical development plans. The company believes that Intrabodies can achie

Vybion will present data on how its drug, INT41, alters a critical event in the development of Huntington`s disease at the 7th Neurodegenerative Conditions Research & Development Conference in Boston on September 9-10, 2013. INT41 is an Intrabody drug delivered by Gene Therapy that blocks gene dysregulation in Huntington`s Disease by neutralizing a toxic fragment of the Huntingtin mutant protein in the nucleus of the cell preventing gene dysregulation.

"We ar

Vybion announces the availability of PharmCode for partnering. PharmCode provides precise and rapid targeting of protein-protein, dimerization, phosphorylation or allele specific intracellular events in a pharmacologically meaningful manner avoiding pleiotropic effects. Most targets have multiple interactions but PharmCode Intrabodies target single events and can assess pathway effects, pathway crosstalk and toxicity analogous to small molecules targeting the same event or interaction,

Vybion has received a $1.3M subcontract on at $7.1M NIH Cooperative Agreement to develop diagnostics for Lassa Virus, a deadly hemorrhagic virus endemic in West Africa. Researchers at Tulane University, in collaboration with Corgenix Medical Corporation, a worldwide developer and marketer of diagnostic test kits, have received a five-year $7.07 million grant from the National Institutes of Health (NIH) for continued development of detection kits for Lassa viral hemorrhagic fever, a seri

Vybion announces the addition of Drs. Matthew DeLisa, William Ball and Andrew Norman to its Scientific Advisory Board. Matthew DeLisa, Ph.D. is on the faculty of Cornell University in the Department of Chemical and Molecular Engineering and the inventor of ProCode. DeLisa`s research group combines protein engineering with genetic and molecular biology approaches to address fundamental issues related to protein transport, protein folding and solubility, and protein synthesis. William Bal

Corgenix Medical Corporation (OTC Bulletin Board: CONX), a worldwide developer and marketer of diagnostic test kits, has announced an expansion of the collaborative effort for developing test kits for viral hemorrhagic fever (VHF) detection... Joining the collaboration is Vybion, Inc., an Ithaca, N.Y., based biotechnology company. Vybion CEO Lee Henderson, Ph.D., stated, "We are pleased to be able to work with Corgenix, Tulane and the other partners. With our deep experience in protein